ºÝºÝߣshows by User: wingibbons / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: wingibbons / Mon, 18 Nov 2013 17:12:20 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: wingibbons Cardiac biomarkers 111813 /slideshow/cardiac-biomarkers-111813/28387593 cardiacbiomarkers111813-131118171220-phpapp01
]]>
]]> Mon, 18 Nov 2013 17:12:20 GMT /slideshow/cardiac-biomarkers-111813/28387593 wingibbons@slideshare.net(wingibbons) Cardiac biomarkers 111813 wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cardiacbiomarkers111813-131118171220-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Cardiac biomarkers 111813 from Winton Gibbons
]]> 1047 3 https://cdn.slidesharecdn.com/ss_thumbnails/cardiacbiomarkers111813-131118171220-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Cardiac biomarkers and lab services /slideshow/cardiac-biomarkers-26877652/26877652 cardiacbiomarkers-131004183904-phpapp01
]]>
]]> Fri, 04 Oct 2013 18:39:04 GMT /slideshow/cardiac-biomarkers-26877652/26877652 wingibbons@slideshare.net(wingibbons) Cardiac biomarkers and lab services wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cardiacbiomarkers-131004183904-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Cardiac biomarkers and lab services from Winton Gibbons
]]> 1017 8 https://cdn.slidesharecdn.com/ss_thumbnails/cardiacbiomarkers-131004183904-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biomarker discovery and validation /slideshow/biomarker-discovery-and-validation/26871225 biomarkerdiscoveryandvalidation-131004131248-phpapp02
]]>
]]> Fri, 04 Oct 2013 13:12:48 GMT /slideshow/biomarker-discovery-and-validation/26871225 wingibbons@slideshare.net(wingibbons) Biomarker discovery and validation wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/biomarkerdiscoveryandvalidation-131004131248-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Biomarker discovery and validation from Winton Gibbons
]]> 555 2 https://cdn.slidesharecdn.com/ss_thumbnails/biomarkerdiscoveryandvalidation-131004131248-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Product market triangulation presentation /slideshow/product-market-triangulation-26794737/26794737 productmarkettriangulation-131002124235-phpapp02
]]>
]]> Wed, 02 Oct 2013 12:42:35 GMT /slideshow/product-market-triangulation-26794737/26794737 wingibbons@slideshare.net(wingibbons) Product market triangulation presentation wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/productmarkettriangulation-131002124235-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Product market triangulation presentation from Winton Gibbons
]]> 302 3 https://cdn.slidesharecdn.com/ss_thumbnails/productmarkettriangulation-131002124235-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Product Market Triangulation /slideshow/product-market-triangulation/26754196 productmarkettriangulation-131001132018-phpapp02
]]>
]]> Tue, 01 Oct 2013 13:20:18 GMT /slideshow/product-market-triangulation/26754196 wingibbons@slideshare.net(wingibbons) Product Market Triangulation wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/productmarkettriangulation-131001132018-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Product Market Triangulation from Winton Gibbons
]]> 379 2 https://cdn.slidesharecdn.com/ss_thumbnails/productmarkettriangulation-131001132018-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Blood screening product and market opportunities /slideshow/blood-screening-product-and-market-opportunities-26631305/26631305 bloodscreeningproductandmarketopportunities-130927163020-phpapp01
]]>
]]> Fri, 27 Sep 2013 16:30:20 GMT /slideshow/blood-screening-product-and-market-opportunities-26631305/26631305 wingibbons@slideshare.net(wingibbons) Blood screening product and market opportunities wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bloodscreeningproductandmarketopportunities-130927163020-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Blood screening product and market opportunities from Winton Gibbons
]]> 469 4 https://cdn.slidesharecdn.com/ss_thumbnails/bloodscreeningproductandmarketopportunities-130927163020-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Health care industry map /slideshow/health-care-industry-map/26361242 healthcareindustrymap-130919160810-phpapp02
]]>
]]> Thu, 19 Sep 2013 16:08:10 GMT /slideshow/health-care-industry-map/26361242 wingibbons@slideshare.net(wingibbons) Health care industry map wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthcareindustrymap-130919160810-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Health care industry map from Winton Gibbons
]]> 1315 6 https://cdn.slidesharecdn.com/ss_thumbnails/healthcareindustrymap-130919160810-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Diagnostics and personalized medicine /slideshow/diagnostics-and-personalized-medicine-26358122/26358122 diagnosticsandpersonalizedmedicine-130919140616-phpapp01
Lecture given for the biotechnology program at the Kellogg Graduate School of Business (NWU)]]>
Lecture given for the biotechnology program at the Kellogg Graduate School of Business (NWU)]]> Thu, 19 Sep 2013 14:06:16 GMT /slideshow/diagnostics-and-personalized-medicine-26358122/26358122 wingibbons@slideshare.net(wingibbons) Diagnostics and personalized medicine wingibbons Lecture given for the biotechnology program at the Kellogg Graduate School of Business (NWU) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/diagnosticsandpersonalizedmedicine-130919140616-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Lecture given for the biotechnology program at the Kellogg Graduate School of Business (NWU)
Diagnostics and personalized medicine from Winton Gibbons
]]> 2773 7 https://cdn.slidesharecdn.com/ss_thumbnails/diagnosticsandpersonalizedmedicine-130919140616-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Protein biomarker capabilities for Nanosphere /slideshow/protein-biomarker-capabilities-for-nanosphere-26352753/26352753 proteinbiomarkercapabilitiesfornanosphere-130919110551-phpapp02
]]>
]]> Thu, 19 Sep 2013 11:05:50 GMT /slideshow/protein-biomarker-capabilities-for-nanosphere-26352753/26352753 wingibbons@slideshare.net(wingibbons) Protein biomarker capabilities for Nanosphere wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/proteinbiomarkercapabilitiesfornanosphere-130919110551-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Protein biomarker capabilities for Nanosphere from Winton Gibbons
]]> 1163 5 https://cdn.slidesharecdn.com/ss_thumbnails/proteinbiomarkercapabilitiesfornanosphere-130919110551-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Practical direct and strategic new product screening framework /slideshow/practical-direct-and-strategic-new-product-screening-framework-infographic/26257587 practicaldirectandstrategicnewproductscreeningframework-infographic-130917013407-phpapp02
]]>
]]> Tue, 17 Sep 2013 01:34:07 GMT /slideshow/practical-direct-and-strategic-new-product-screening-framework-infographic/26257587 wingibbons@slideshare.net(wingibbons) Practical direct and strategic new product screening framework wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/practicaldirectandstrategicnewproductscreeningframework-infographic-130917013407-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Practical direct and strategic new product screening framework from Winton Gibbons
]]> 224 3 https://cdn.slidesharecdn.com/ss_thumbnails/practicaldirectandstrategicnewproductscreeningframework-infographic-130917013407-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Next gen sequencing translation to clinic /slideshow/next-gen-sequencing-translation-to-clinic-infographic/26250581 nextgensequencingtranslationtoclinic-infographic-130916185735-phpapp01
]]>
]]> Mon, 16 Sep 2013 18:57:35 GMT /slideshow/next-gen-sequencing-translation-to-clinic-infographic/26250581 wingibbons@slideshare.net(wingibbons) Next gen sequencing translation to clinic wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nextgensequencingtranslationtoclinic-infographic-130916185735-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Next gen sequencing translation to clinic from Winton Gibbons
]]> 187 2 https://cdn.slidesharecdn.com/ss_thumbnails/nextgensequencingtranslationtoclinic-infographic-130916185735-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Performing market assessments for medical products /slideshow/performing-market-assessments-for-medical-products-infographic/26243683 performingmarketassessmentsformedicalproducts-infographic-130916143247-phpapp02
]]>
]]> Mon, 16 Sep 2013 14:32:46 GMT /slideshow/performing-market-assessments-for-medical-products-infographic/26243683 wingibbons@slideshare.net(wingibbons) Performing market assessments for medical products wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/performingmarketassessmentsformedicalproducts-infographic-130916143247-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Performing market assessments for medical products from Winton Gibbons
]]> 239 2 https://cdn.slidesharecdn.com/ss_thumbnails/performingmarketassessmentsformedicalproducts-infographic-130916143247-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Strategic practical product screening framework /slideshow/strategic-practical-product-screening-framework/26186567 strategicpracticalproductscreeningframework-130914013657-phpapp02
]]>
]]> Sat, 14 Sep 2013 01:36:57 GMT /slideshow/strategic-practical-product-screening-framework/26186567 wingibbons@slideshare.net(wingibbons) Strategic practical product screening framework wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/strategicpracticalproductscreeningframework-130914013657-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Strategic practical product screening framework from Winton Gibbons
]]> 444 3 https://cdn.slidesharecdn.com/ss_thumbnails/strategicpracticalproductscreeningframework-130914013657-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Heart Failure - large market opportunities for new biomarkers /slideshow/heart-failure-large-market-opportunities-for-new-biomarkers/26181004 heartfailure-largemarketopportunitiesfornewbiomarkers-130913182456-phpapp01
]]>
]]> Fri, 13 Sep 2013 18:24:56 GMT /slideshow/heart-failure-large-market-opportunities-for-new-biomarkers/26181004 wingibbons@slideshare.net(wingibbons) Heart Failure - large market opportunities for new biomarkers wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/heartfailure-largemarketopportunitiesfornewbiomarkers-130913182456-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Heart Failure - large market opportunities for new biomarkers from Winton Gibbons
]]> 530 4 https://cdn.slidesharecdn.com/ss_thumbnails/heartfailure-largemarketopportunitiesfornewbiomarkers-130913182456-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Blood Screening Opportunities for New Testing of Donations /slideshow/blood-screening-report/26148436 bloodscreeningreport-130912163423-phpapp01
The blood screen testing market is apparently plateauing, with risks of decline over the next few years, as more patents expire. Additionally, there have been structural industry changes that could accelerate this, particularly the acquisition of Gen-Probe by Hologic. The acquisition also affects Novartis in the nucleic acid testing part of the business. However, there are many untapped markets and many regions where blood donations themselves should be higher to have modern public health. This report shows that the future market for blood screening should be very robust for those firms that pursue the right regions with the right products.]]>
The blood screen testing market is apparently plateauing, with risks of decline over the next few years, as more patents expire. Additionally, there have been structural industry changes that could accelerate this, particularly the acquisition of Gen-Probe by Hologic. The acquisition also affects Novartis in the nucleic acid testing part of the business. However, there are many untapped markets and many regions where blood donations themselves should be higher to have modern public health. This report shows that the future market for blood screening should be very robust for those firms that pursue the right regions with the right products.]]> Thu, 12 Sep 2013 16:34:23 GMT /slideshow/blood-screening-report/26148436 wingibbons@slideshare.net(wingibbons) Blood Screening Opportunities for New Testing of Donations wingibbons The blood screen testing market is apparently plateauing, with risks of decline over the next few years, as more patents expire. Additionally, there have been structural industry changes that could accelerate this, particularly the acquisition of Gen-Probe by Hologic. The acquisition also affects Novartis in the nucleic acid testing part of the business. However, there are many untapped markets and many regions where blood donations themselves should be higher to have modern public health. This report shows that the future market for blood screening should be very robust for those firms that pursue the right regions with the right products. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bloodscreeningreport-130912163423-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The blood screen testing market is apparently plateauing, with risks of decline over the next few years, as more patents expire. Additionally, there have been structural industry changes that could accelerate this, particularly the acquisition of Gen-Probe by Hologic. The acquisition also affects Novartis in the nucleic acid testing part of the business. However, there are many untapped markets and many regions where blood donations themselves should be higher to have modern public health. This report shows that the future market for blood screening should be very robust for those firms that pursue the right regions with the right products.
Blood Screening Opportunities for New Testing of Donations from Winton Gibbons
]]> 1474 4 https://cdn.slidesharecdn.com/ss_thumbnails/bloodscreeningreport-130912163423-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Market assessment for medical diagnostic products /slideshow/market-assessment-for-medical-diagnostic-products/26148434 marketassessmentformedicaldiagnosticproducts-130912163417-phpapp02
]]>
]]> Thu, 12 Sep 2013 16:34:17 GMT /slideshow/market-assessment-for-medical-diagnostic-products/26148434 wingibbons@slideshare.net(wingibbons) Market assessment for medical diagnostic products wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/marketassessmentformedicaldiagnosticproducts-130912163417-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Market assessment for medical diagnostic products from Winton Gibbons
]]> 941 2 https://cdn.slidesharecdn.com/ss_thumbnails/marketassessmentformedicaldiagnosticproducts-130912163417-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Extracting clinical value from next gen sequencing /slideshow/extracting-clinical-value-from-next-gen-sequencing/26148432 extractingclinicalvaluefromnextgensequencing-130912163416-phpapp02
It has become cliché in the clinical environment, and genetic sequencing realm, that there is a glut of sequence data. The conundrum is how to translate or transform the overabundance of data into clinically useful knowledge. This situation has only grown more acute since the introduction of next gen sequencing. To arrive at the clinical knowledge, there needs to be a concentric series of integrated capabilities, and the necessary capacity. The core is of course the sequencing process itself, the IT tools to process it, and the human expertise. However, the essentials in the first two aspects, sequencing and IT, need to exist, and thereby create opportunities for organizations. As there are numerable subtleties even within the essential capabilities, a single organization may not be able to develop all under one roof. Nor may certain abilities yet exist sufficiently. However, a complete ecosystem at best, or promising potential at worst, is still required. The attached presentation illustrates the high-level transformation frameworks for this, and the subsequent translation of data to be clinically useful.]]>
It has become cliché in the clinical environment, and genetic sequencing realm, that there is a glut of sequence data. The conundrum is how to translate or transform the overabundance of data into clinically useful knowledge. This situation has only grown more acute since the introduction of next gen sequencing. To arrive at the clinical knowledge, there needs to be a concentric series of integrated capabilities, and the necessary capacity. The core is of course the sequencing process itself, the IT tools to process it, and the human expertise. However, the essentials in the first two aspects, sequencing and IT, need to exist, and thereby create opportunities for organizations. As there are numerable subtleties even within the essential capabilities, a single organization may not be able to develop all under one roof. Nor may certain abilities yet exist sufficiently. However, a complete ecosystem at best, or promising potential at worst, is still required. The attached presentation illustrates the high-level transformation frameworks for this, and the subsequent translation of data to be clinically useful.]]> Thu, 12 Sep 2013 16:34:16 GMT /slideshow/extracting-clinical-value-from-next-gen-sequencing/26148432 wingibbons@slideshare.net(wingibbons) Extracting clinical value from next gen sequencing wingibbons It has become cliché in the clinical environment, and genetic sequencing realm, that there is a glut of sequence data. The conundrum is how to translate or transform the overabundance of data into clinically useful knowledge. This situation has only grown more acute since the introduction of next gen sequencing. To arrive at the clinical knowledge, there needs to be a concentric series of integrated capabilities, and the necessary capacity. The core is of course the sequencing process itself, the IT tools to process it, and the human expertise. However, the essentials in the first two aspects, sequencing and IT, need to exist, and thereby create opportunities for organizations. As there are numerable subtleties even within the essential capabilities, a single organization may not be able to develop all under one roof. Nor may certain abilities yet exist sufficiently. However, a complete ecosystem at best, or promising potential at worst, is still required. The attached presentation illustrates the high-level transformation frameworks for this, and the subsequent translation of data to be clinically useful. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/extractingclinicalvaluefromnextgensequencing-130912163416-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> It has become cliché in the clinical environment, and genetic sequencing realm, that there is a glut of sequence data. The conundrum is how to translate or transform the overabundance of data into clinically useful knowledge. This situation has only grown more acute since the introduction of next gen sequencing. To arrive at the clinical knowledge, there needs to be a concentric series of integrated capabilities, and the necessary capacity. The core is of course the sequencing process itself, the IT tools to process it, and the human expertise. However, the essentials in the first two aspects, sequencing and IT, need to exist, and thereby create opportunities for organizations. As there are numerable subtleties even within the essential capabilities, a single organization may not be able to develop all under one roof. Nor may certain abilities yet exist sufficiently. However, a complete ecosystem at best, or promising potential at worst, is still required. The attached presentation illustrates the high-level transformation frameworks for this, and the subsequent translation of data to be clinically useful.
Extracting clinical value from next gen sequencing from Winton Gibbons
]]> 1047 4 https://cdn.slidesharecdn.com/ss_thumbnails/extractingclinicalvaluefromnextgensequencing-130912163416-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Process to divest therapeutic pipelines /slideshow/process-to-divest-therapeutic-pipelines/26148430 processtodivesttherapeuticpipelines-130912163415-phpapp01
]]>
]]> Thu, 12 Sep 2013 16:34:14 GMT /slideshow/process-to-divest-therapeutic-pipelines/26148430 wingibbons@slideshare.net(wingibbons) Process to divest therapeutic pipelines wingibbons <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/processtodivesttherapeuticpipelines-130912163415-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Process to divest therapeutic pipelines from Winton Gibbons
]]> 383 4 https://cdn.slidesharecdn.com/ss_thumbnails/processtodivesttherapeuticpipelines-130912163415-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-wingibbons-48x48.jpg?cb=1625854181 My background merges industry, consulting, and financial services, predominantly for innovative clinical diagnostic, life science, and therapeutic companies. These have been based on biotechnology, nanotechnology, and microfluidics, as well as novel biomarkers. This experience enables me to contribute highly as a senior leader or consultant. Most recently, I was Senior Vice President for Corporate Development at Agena Bioscience, which makes genetic testing equipment. For the clinical diagnostic and life science fields, I have also been a senior leader at Roche, Merck, Biosite, Siloam Bioscience, and Nanosphere. In financial services, I was the group head for healthcare equity research,... wingibbons.wordpress.com https://cdn.slidesharecdn.com/ss_thumbnails/cardiacbiomarkers111813-131118171220-phpapp01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/cardiac-biomarkers-111813/28387593 Cardiac biomarkers 111813 https://cdn.slidesharecdn.com/ss_thumbnails/cardiacbiomarkers-131004183904-phpapp01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/cardiac-biomarkers-26877652/26877652 Cardiac biomarkers and... https://cdn.slidesharecdn.com/ss_thumbnails/biomarkerdiscoveryandvalidation-131004131248-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/biomarker-discovery-and-validation/26871225 Biomarker discovery an...